{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-016467","form_type":"8-K","ticker":"SPRB","cik":"0001683553","company_name":"SPRUCE BIOSCIENCES, INC.","filed_at":"2022-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.652722+00:00","generated_at":"2026-06-24T01:28:16.283326+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Spruce Biosciences reports Q2 2022 net loss of $11.9M; cash $99.1M; updates on CAH trials and leadership","bullets":["Net loss of $11.9M for Q2 2022 (vs $11.8M Q2 2021); R&D spend $9.1M, flat YoY.","Cash, equivalents and investments $99.1M as of June 30, 2022.","CAHmelia-203 surpassed 25% enrollment; CAHmelia-204 approaching 25% enrollment.","Appointed P.J. Ramtin as SVP of Business Operations; two new tildacerfont method-of-use patents issued, exclusivity through 2038.","Abstract on Phase 2a CAH data accepted for oral presentation at ICE 2022 (Aug 27)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-016467","json":"https://secwatch.observer/filing/0000950170-22-016467.json","markdown":"https://secwatch.observer/filing/0000950170-22-016467.md","text":"https://secwatch.observer/filing/0000950170-22-016467.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1683553/000095017022016467/0000950170-22-016467-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1683553/000095017022016467/sprb-20220810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:28:16.283326+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}